Surya Sandarsh, Rosenquist Peter B, McCall W Vaughn
From the Department of Psychiatry and Health Behavior, Medical College of Georgia, Georgia Regents University, Augusta, GA.
J ECT. 2016 Mar;32(1):62-4. doi: 10.1097/YCT.0000000000000245.
This is the first case report of the safety of therapeutic repetitive transcranial magnetic stimulation (rTMS) in a patient with an intracranial space-occupying lesion who had recurrent major depression. In this case, the intracranial space-occupying lesion was a mixed cystic and solid enhancing pineal region mass measuring approximately 16.9 × 12.2 × 15.5 mm. The patient remitted from depression with 36 sessions of dorsolateral prefrontal cortex rTMS treatments over a 6-week period. During the rTMS treatment course, patient's medication list included bupropion that potentially can increase the risk for a seizure and topiramate that potentially can reduce the risk for seizure associated with the treatment. The patient tolerated the rTMS treatment well, reporting only transient headache and discomfort at the site of stimulation after the treatment. She tolerated the procedure well and had no incidental seizure activity throughout her treatment sessions.
这是关于一名患有颅内占位性病变且复发性重度抑郁症患者接受治疗性重复经颅磁刺激（rTMS）安全性的首例病例报告。在此病例中，颅内占位性病变是一个位于松果体区的混合性囊性及实性强化肿块，大小约为16.9×12.2×15.5毫米。该患者在6周内接受了36次背外侧前额叶皮质rTMS治疗后抑郁症缓解。在rTMS治疗过程中，患者的用药清单包括可能增加癫痫发作风险的安非他酮和可能降低与治疗相关癫痫发作风险的托吡酯。患者对rTMS治疗耐受性良好，仅报告治疗后在刺激部位出现短暂头痛和不适。她对该治疗过程耐受性良好，在整个治疗期间未发生偶发性癫痫活动。
